Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices

Evidence from real-world clinical settings is lacking with regard to first-line immunotherapy plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to describe outcomes for patients treated with first-line pembrolizumab-combination therapy for metastatic nonsquamous...

Descripción completa

Detalles Bibliográficos
Autores principales: Velcheti, Vamsidhar, Hu, Xiaohan, Piperdi, Bilal, Burke, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080779/
https://www.ncbi.nlm.nih.gov/pubmed/33911121
http://dx.doi.org/10.1038/s41598-021-88453-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080779/
https://www.ncbi.nlm.nih.gov/pubmed/33911121
http://dx.doi.org/10.1038/s41598-021-88453-8

Ejemplares similares